Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: The hepatologist's view

Minerva Gastroenterologica e Dietologica

Volumn 51, Issue 1, 2005, Pages 55-61

  Pellicano, R ^a,c   Smedile, A ^a   Peyre, S ^b   Astegiano, M ^a   Saracco, G ^a   Bonardi, R ^a   Rizzetto, M ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b Unit of Gastroenterology   (Italy)

^c Struttura Complessa di Neurologia   (Italy)

Author keywords

Autoantobodies; Autoimmunity; Hepatitis C; Interferon

Indexed keywords

AUTOANTIBODY; INTERFERON; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; ANTIVIRUS AGENT;

ABSENCE OF SIDE EFFECTS; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE THROMBOCYTOPENIA; AUTOIMMUNITY; CELIAC DISEASE; GASTRITIS; HEMATOLOGIC MALIGNANCY; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LARYNX PAPILLOMATOSIS; LUPUS LIKE SYNDROME; MYASTHENIA; PATIENT COMPLIANCE; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; RISK FACTOR; SJOEGREN SYNDROME; THYROID DISEASE; THYROIDITIS; AUTOIMMUNE THYROIDITIS; COMPARATIVE STUDY; FEMALE; IMMUNOLOGY; MALE; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROID GLAND;

ANTIVIRAL AGENTS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; FEMALE; HEPATITIS C, CHRONIC; HEPATITIS, AUTOIMMUNE; HUMANS; INTERFERONS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; THYROID GLAND; THYROIDITIS, AUTOIMMUNE;

EID: 19444373283     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B 1957;147:258-67.
2. Vial T, Bailly F, Descotes J, Trepo C. Side-effects of interferon-alpha. Gastroenterol Clin Biol 1996;20:462-83. French.
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
4. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237-44.
5. Dumoulin FL, Leifeld L, Sauerbach T, Spengler U. Autoimmunity induced by interferon-alfa therapy for chronic viral hepatitis. Biomed Pharmacother 1999;53:242-54.
6. Strader DB. Understudied populations with hepatitis C. Hepatology 2002;36:S226-36.
7. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (α/β) in immunity and autoimmunity. Annu Rev Immunol 2005;23:307-35.
8. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, Vazquez R, Ocete E, Olea N et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med 1998;13:1445-8.
9. Carella C, Mazziotti G, Morisco F, Manganella G, Rotondi M, Tuccillo C et al. Long-term outcome of interferon-α-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab 2001;86: 1925-9.
10. Rocco A, Gargano S, Provenzano A, Nardone M, De Sanctis GM, Altavilla N et al. Incidence of autoimmune thyroiditis in interferon-alpha treated and untreated patients with chronic hepatitis C virus infection. Neuroendocrinol Lett 2001;22:39-44.
11. Paranà R, Cruz, Lyra, Cruz T. Subacute thyroiditis during treatment with combination therapy (interferon plus ribavirin) for hepatitis C virus. J Viral Hepatitis 2000;7:393-5.
12. Wong V, Fu AX, George J, Cheung NW. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol 2002;56:793-8.
13. Dalgard O, Bjøro K, Helium K, Myrvang B, Bjøro T, Haug E et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med 2002;251:400-6.
14. Mazziotti G, Sorvillo F, Stornaiuolo G, Rotondi M, Morisco F, Ruberto M et al. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study. J Endocrinol Invest 2002;25:624-30.
15. Durelli L, Ferrero B, Oggero A, Verdun E, Ghezzi A, Montanari E et al. Thyroid function and autoimmunity during interferon b-1b treatment: a multicenter prospective study. J Clin Endocrinol Metab 2001;86:3525-32.
16. Pellicano R, Smedile A, Touscoz A, Berrutti M, Pitaro M, Rizzetto M. Autoimmunity in HCV naïve patients treated with r-hIFN beta-1a. Dig Liver Dis 2003;35:A4-P3.
17. Piquer S, Hernandez C, Enriquez J, Ross A, Esteban JI, Genesca J et al. Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: effect of treatment with interferon. J Lab Clin Med 2001;137:38-42.
18. Floreani A, Chiaramonte M, Greggio NA, Fabris P, De Lazzari F, Naccarato R et al. Organ-specific autoimmunity and genetic predisposition in interferon-treated HCV-related chronic hepatitis patients. Ital J Gastroenterol Hepatol 1998;30:71-6
19. Devendra D, Eisenbarth GS. Interferon alpha-a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin Immunol 2004;111:225-33.
20. Wesche B, Jaeckel E, Trautwein C, Wedemeyer H, Falorni A, Frank H et al. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001;48:378-83.
21. Muratori L, Lenzi M, Cataleta M, Giostra F, Cassani F, Ballardini G et al. Interferon therapy in liver/kydney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 1994;21:199-203.
22. Todros L, Saracco G, Durazzo M, Abate ML, Touscoz G, Scaglione L et al. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatology 1995;22:1374-8.
23. Cacopardo B, Benanti F, Brancati G. Leucocyte interferon-a retreatment for chronic hepatitis C patients previously intolerant to other interferons. J Viral Hepat 1998;5:333-9.
24. Stroffolini T, Colloredo G, Gaeta GB, Sonzogni A, Angeletti S, Marignani M et al. Does an "autoimmune" profile affect the clinical profile of chronic hepatitis C? An Italian multicentre survey. J Viral Hepat 2004;11:257-62.
25. Wilson L, Widman D, Dikman SH, Gorevic PD. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum 2002;32:163-73.
26. Crow MK, Kirou KA. Interferon-alpha in systemic lupus erythematosus. Curr Opin Rheumatol 2004;16:541-7.
27. Pouthier D, Theissen F, Humbel R-L. Lupus syndrome, hypothyroidism and bullous skin lesions after interferon alfa therapy for hepatitis C in a haemodialysis patient. Nephrol Dial Transplant 2002;17:174.
28. Durante-Mangoni E, Iardino P, Resse M, Cesaro G, Sica A, Farzati Ruggiero G et al. Silent celiac disease in chronic hepatitis C: impact of interferon treatment on the disease onset and clinical outcome. J Clin Gastroenterol 2004;38:901-5.
29. Fabbri C, Jaboli F, Giovanelli S, Azzaroli F, Pezzoli A, Accogli E et al. Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy. World J Gastroenterol 2003;9:1487-90.